**Teaching unit 08**

1. Classification of monoclonal antibodies used in the tumor treatment.
2. Explain blocking signaling pathways by using unconjugated mAbs. What therapeutic antibodies use this mechanism of action?
3. Explain complement-dependent cytotoxicity (CDC) pathways by using unconjugated mAbs. Clinical applying of mAb with this mechanism of action.
4. Explain antibody-dependent cellular phagocytosis (ADCP) by using unconjugated mAbs. Clinical applying of mAb with this mechanism action.
5. Explain antibody-dependent cellular cytotoxicity (ADCC) by using unconjugated mAbs. What therapeutic antibodies use this mechanism of action?
6. Targeting tumor stroma and vasculature with unconjugated mAbs.
7. Checkpoint blockade immunotherapy.
8. Advantages of antibody-drug conjugates (ADCs)
9. Target tumor antigen selection for ADCs.
10. Effector mechanisms of conjugated antibody or antibody–drug conjugates (ADCs)
11. Gemtuzumab ozogamicin (GO) and T-DM1.
12. Immunotoxins and radioactive conjugated mAbs.
13. Clasiffication and mechanisms of action of bispecific antibodies.
14. What bispecific antibodies are used in tumor therapy?